ArticleParasites & vectors2019
Evaluation of the in vitro and in vivo inhibitory effect of thymoquinone on piroplasm parasites.
Article in Parasites & vectors, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Recent advancements in phytotherapeutics for controlling babesiosis and theileriosis.Tropical animal health and production · 2026Review
- Could Mesquite (Animals : an open access journal from MDPI · 2025Review
- Article
- The Use of Natural Bioactive Nutraceuticals in the Management of Tick-Borne Illnesses.Microorganisms · 2023Review
- Article
- Imidazo[1,2-a]pyridine: a Highly Potent Therapeutic Agent Clears Piroplasm Infection In Vitro.Acta parasitologica · 2023Article
- In Vitro Inhibitory Effects and Bioinformatic Analysis of Norfloxacin and Ofloxacin on Piroplasm.Acta parasitologica · 2023Article
- Evaluation of the Inhibitory Effect ofJournal of tropical medicine · 2023Article
- Antiparasitic activity of FLLL-32 against fourFrontiers in pharmacology · 2023Article
- Repurposing of the Malaria Box for Babesia microti in mice identifies novel active scaffolds against piroplasmosis.Parasites & vectors · 2022Article
- Evaluation of theJournal of advanced veterinary and animal research · 2022Article
- Effect of methanolic extract fromVeterinary world · 2022Article
- Pomegranate (Journal of parasitology research · 2022Article
- Review
- Reserpine-induced altered neuro-behavioral, biochemical and histopathological assessments prevent by enhanced antioxidant defence system of thymoquinone in mice.Metabolic brain disease · 2021Article
- Compounds from the Medicines for Malaria Venture Box Inhibit In Vitro Growth ofMolecules (Basel, Switzerland) · 2021Article
- Discovering the Potent Inhibitors AgainstFrontiers in veterinary science · 2021Article
- Bovine Babesiosis in Turkey: Impact, Current Gaps, and Opportunities for Intervention.Pathogens (Basel, Switzerland) · 2020Review
- Twenty Years of Equine Piroplasmosis Research: Global Distribution, Molecular Diagnosis, and Phylogeny.Pathogens (Basel, Switzerland) · 2020Review
- Myrrh OilPathogens (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundDeveloping new antibabesial drugs with a low toxic effect to the animal and with no resistance from Babesia parasites is in urgent demand. In this concern, the antimalarial, anticancer and antioxidant effect of thymoquinone (TQ), a phytochemical compound found in the plant Nigella sativa, has been reported. Therefore, in the present study, the antibabesial effect of this compound was evaluated on the growth of piroplasm parasites.
resultsSignificant inhibition (P < 0.05) of the in vitro growth of piroplasm parasites were observed after treatment by TQ with IC
conclusionsThe obtained results indicate that thymoquinone might be a promising medicinal compound for use in the treatment of animal piroplasmosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.